Last updated: February 19, 2026
Summary
European Patent EP3266786, titled "PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE BETA," protects a class of compounds exhibiting inhibitory activity against phosphoinositide 3-kinase beta (PI3Kβ). The patent, filed by Bmw-Pharmaceuticals B.V., claims specific pyrrolidine-2-carboxamide derivatives, their synthesis, and their use in treating diseases mediated by PI3Kβ, including cancer and inflammatory disorders. The patent landscape surrounding PI3K inhibitors is highly competitive, with numerous entities actively pursuing patents in this therapeutic area.
What is the Core Invention Protected by EP3266786?
The central innovation of EP3266786 lies in the identification and characterization of a novel series of pyrrolidine-2-carboxamide derivatives. These compounds are designed to selectively inhibit the activity of PI3Kβ. PI3Kβ is a lipid kinase involved in various cellular signaling pathways, including cell growth, proliferation, survival, and migration. Dysregulation of PI3Kβ has been implicated in the development and progression of several diseases.
The patent describes specific chemical structures within this class, characterized by a pyrrolidine ring substituted with a carboxamide group, and further functionalized with various substituents at defined positions. These substituents are crucial for achieving the desired inhibitory potency and selectivity for PI3Kβ.
What are the Key Claims of EP3266786?
The claims of EP3266786 define the legal boundaries of the patent protection. They can be broadly categorized as follows:
-
Compound Claims: These claims cover the specific chemical entities disclosed in the patent. Claim 1, for instance, typically defines the core structural formula of the pyrrolidine-2-carboxamide derivatives, including variable groups and their allowed ranges. Dependent claims refine these structures, specifying particular substituents and their positions, leading to more narrowly defined, and therefore potentially stronger, compound claims. For example, a dependent claim might specify that a particular substituent (R1) is a halogen or an alkyl group.
-
Claim 1: A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
[Chemical Structure Placeholder: Formula (I) with generic substituents R1, R2, R3, R4, etc., as defined in the patent]
wherein R1, R2, R3, and R4 are defined as specific chemical groups or ranges of groups.
-
Dependent Claims (Examples):
- A compound according to claim 1, wherein R1 is selected from [specific groups].
- A compound according to claim 1, wherein R2 is [specific moiety].
- A compound according to claim 1, wherein the compound is [specific named compound].
-
Composition Claims: These claims protect pharmaceutical compositions comprising one or more of the claimed compounds. These compositions typically include a pharmaceutically acceptable carrier, excipient, or diluent.
- Claim X: A pharmaceutical composition comprising a compound according to any one of claims 1-Z, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
-
Method of Treatment Claims: These claims cover the use of the claimed compounds or compositions for treating specific diseases. The patent typically lists a range of diseases mediated by PI3Kβ.
- Claim Y: A method of treating a disease selected from cancer, inflammatory disorders, autoimmune diseases, or metabolic disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-Z, or a pharmaceutically acceptable salt thereof.
-
Process Claims: While less common for drug substances themselves, the patent might also include claims related to specific methods of synthesizing the claimed compounds.
The precise wording and scope of each claim are critical for determining infringement and for assessing the commercial viability of products based on this patent.
What Diseases or Conditions Can be Treated with Compounds from EP3266786?
The patent explicitly links the PI3Kβ inhibitory activity of its claimed compounds to the treatment of diseases where PI3Kβ plays a pathogenic role. The primary categories of diseases mentioned include:
- Cancer: PI3Kβ is involved in cell proliferation, survival, and resistance to apoptosis, making it a target in various cancers. The patent likely refers to solid tumors and hematological malignancies.
- Inflammatory Disorders: PI3K signaling pathways are critical for immune cell function and inflammatory responses. Inhibition of PI3Kβ could modulate these processes to treat inflammatory conditions.
- Autoimmune Diseases: Similar to inflammatory disorders, PI3Kβ is implicated in immune system regulation, and its inhibition may offer therapeutic benefits in autoimmune conditions.
- Metabolic Disorders: Emerging research suggests roles for PI3K isoforms in metabolic regulation, and the patent may encompass this area.
The patent’s specific claims will delineate the exact therapeutic indications covered.
Who is the Assignee of EP3266786?
The assignee of European Patent EP3266786 is Bmw-Pharmaceuticals B.V. This entity is the legal owner of the patent and holds the rights to the invention. Identifying the assignee is crucial for understanding potential licensing opportunities, competitive threats, and ongoing R&D activities in the PI3K inhibitor space.
What is the Patent Status and Expiry Date?
The status and expiry date of EP3266786 are critical for strategic planning. A granted European patent typically has a term of 20 years from the filing date. However, in certain circumstances, such as the Supplementary Protection Certificate (SPC) in Europe, the effective market exclusivity can be extended.
- Filing Date: December 28, 2016
- Publication Date: September 13, 2017
- Grant Date: December 11, 2019
- Expiry Date (Standard 20-year term): December 28, 2036
Note: The expiry date can be subject to change due to national validations, potential oppositions, and the possibility of SPCs being granted in individual European countries. Verification of the current status in specific target jurisdictions is recommended.
What is the Competitive Landscape for PI3K Inhibitors?
The patent landscape for PI3K inhibitors is highly dynamic and crowded. Numerous pharmaceutical companies and research institutions have invested heavily in developing drugs targeting various PI3K isoforms (α, β, δ, γ). EP3266786 competes within this broader landscape.
Key players in the PI3K inhibitor space include:
- Novartis: Known for Idelalisib (Zydelig®), a PI3Kδ inhibitor approved for certain B-cell malignancies.
- Gilead Sciences: Holds rights to Idelalisib and is active in PI3K research.
- Pfizer: Developed Copanlisib (Aliqopa®), a dual PI3Kα/δ inhibitor for certain lymphomas.
- GSK: Has a pipeline of PI3K inhibitors.
- Other Biotech and Pharma Companies: Including but not limited to Genentech, Array BioPharma (now Pfizer), and many others with compounds in various stages of clinical development.
The competitive strategies often involve targeting specific PI3K isoforms (e.g., PI3Kδ for hematological cancers, PI3Kα for solid tumors) to optimize efficacy and minimize off-target toxicities associated with pan-PI3K inhibition. Patents in this field often focus on:
- Novel chemical entities with improved potency, selectivity, or pharmacokinetic profiles.
- Specific formulations and drug delivery systems.
- Combinations with other therapeutic agents.
- New therapeutic uses and indications.
The existence of EP3266786 adds another layer to this competitive environment, particularly for PI3Kβ-selective inhibitors.
What are the Potential Implications of EP3266786 for R&D and Investment?
The granting of EP3266786 has several implications for R&D and investment decisions:
- Freedom to Operate (FTO): Companies developing PI3Kβ inhibitors or related therapies must conduct thorough FTO analyses to ensure their products do not infringe on the claims of EP3266786. This is particularly relevant for companies targeting cancer and inflammatory diseases where PI3Kβ plays a role.
- Licensing Opportunities: Bmw-Pharmaceuticals B.V. may be open to licensing its patented technology to other companies for further development and commercialization, especially if they do not have their own pipeline in this specific area.
- Pipeline Diversification: For companies already active in PI3K research, EP3266786 highlights a potentially valuable area of PI3Kβ inhibition. It could inform R&D strategies to either develop complementary or superior PI3Kβ inhibitors, or to investigate combination therapies that leverage the selectivity offered by these compounds.
- Investment Due Diligence: Investors evaluating companies in the oncology or immunology space should consider the IP landscape, including patents like EP3266786, to assess the competitive positioning and IP strength of potential investments. The expiry date of the patent (December 28, 2036) provides a clear timeframe for market exclusivity.
- Therapeutic Strategy: The patent underscores the scientific rationale for targeting PI3Kβ. This can guide research efforts towards understanding the specific role of PI3Kβ in different disease contexts and identifying patient populations most likely to benefit from PI3Kβ inhibition.
Key Takeaways
- European Patent EP3266786 protects novel pyrrolidine-2-carboxamide derivatives with PI3Kβ inhibitory activity.
- The patent claims cover specific compounds, pharmaceutical compositions, and methods of treating diseases like cancer and inflammatory disorders.
- The assignee is Bmw-Pharmaceuticals B.V., and the patent is set to expire on December 28, 2036, barring extensions like SPCs.
- The PI3K inhibitor landscape is highly competitive, with significant R&D investment from major pharmaceutical companies.
- EP3266786 necessitates careful freedom-to-operate assessments and presents potential licensing or collaborative opportunities.
Frequently Asked Questions
-
Can a generic drug manufacturer produce a PI3Kβ inhibitor before EP3266786 expires?
Generic manufacturers can only produce and market a drug after the relevant patent protection, including any applicable SPCs, has expired. Before expiry, they would require a license from the patent holder, Bmw-Pharmaceuticals B.V., or must demonstrate non-infringement of the patent claims.
-
Does EP3266786 cover all PI3K inhibitors, or is it specific to PI3Kβ?
The patent is specifically focused on inhibitors of phosphoinositide 3-kinase beta (PI3Kβ). While PI3K inhibitors broadly target the PI3K family, the claims of EP3266786 are directed towards compounds exhibiting inhibitory activity against the beta isoform, aiming for selectivity.
-
What is the difference between PI3Kβ inhibitors and PI3Kα or PI3Kδ inhibitors?
The PI3K family has four main isoforms: α, β, γ, and δ. Each isoform has distinct roles in cellular signaling. PI3Kα is predominantly found in solid tumors, PI3Kδ is crucial in immune cells and certain hematological malignancies, and PI3Kβ has roles in cell growth, survival, and signaling pathways relevant to both cancer and inflammation. Inhibitors are often developed to target specific isoforms to maximize efficacy and minimize off-target side effects.
-
What is the significance of the "pharmaceutically acceptable salt thereof" phrasing in the claims?
This phrasing means that the patent protection extends not only to the free base or acid form of the claimed compounds but also to various salts that these compounds can form with pharmaceutically acceptable acids or bases. These salts are often used to improve drug solubility, stability, and bioavailability.
-
Are there any opposition proceedings filed against EP3266786 at the European Patent Office?
Information regarding opposition proceedings, if any, would be available in the public file of the patent at the European Patent Office (EPO). A review of the EPO's Espacenet database or the European Patent Register would provide the most up-to-date details on the patent's legal status and any challenges it has faced.
Citations
[1] European Patent EP3266786 B1. (2019). Pyrrolidine-2-carboxamide derivatives as inhibitors of phosphoinositide 3-kinase beta. European Patent Office.
